NeuroDerm Announces Patient Enrollment in Long-Term Safety Trial of ND0612 for PD


(May 16, 2016) - NeuroDerm announced the start of patient enrollment in a long-term safety study (trial 012) of the company’s continuously administered subcutaneous levodopa/carbidopa (LD/CD) formulation used in both ND0612H and ND0612L. The one-year international, open label study will investigate the long-term safety of low and high dose regimens of ND0612.  Read more…

Click for a printer friendly version

Back to top